Kawasaki Disease

8
Pipeline Programs
4
Companies
7
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
2
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 6 programs with unclassified modality

On Market (1)

Approved therapies currently available

Swedish Orphan Biovitrum
KINERETApproved
anakinra
Swedish Orphan Biovitrum
Interleukin-1 Receptor Antagonist [EPC]subcutaneous2001

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Swedish Orphan Biovitrum
2 programs
1
1
1
ANAKINRAPhase 31 trial
AnakinraPhase 21 trial
Active Trials
NCT02390596CompletedEst. Feb 2019
NCT04656184RecruitingEst. Mar 2027
GC Biopharma
GC BiopharmaKorea - Yongin
2 programs
2
Immunoglobulin GPhase 41 trial
immunoglobulin GPhase 41 trial
Active Trials
NCT04003844CompletedEst. Nov 2019
NCT01524939CompletedEst. Sep 2012
Lantheus Medical Imaging
2 programs
1
1
SestamibiPhase 31 trial
Technetium Tc99m SestamibiPhase 1/21 trial
Active Trials
NCT00162045CompletedEst. Jun 2007
NCT00162032CompletedEst. Dec 2010
Bristol Myers Squibb
1 program
1
pravastatinPhase 2Small Molecule1 trial
Active Trials
NCT00305201Withdrawn0Est. May 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
GC BiopharmaImmunoglobulin G
GC Biopharmaimmunoglobulin G
Swedish Orphan BiovitrumANAKINRA
Lantheus Medical ImagingSestamibi
Swedish Orphan BiovitrumAnakinra
Bristol Myers Squibbpravastatin
Lantheus Medical ImagingTechnetium Tc99m Sestamibi

Clinical Trials (7)

NCT04003844GC BiopharmaImmunoglobulin G

Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease

Start: Feb 2019Est. completion: Nov 2019
Phase 4Completed
NCT01524939GC Biopharmaimmunoglobulin G

Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease

Start: Jan 2012Est. completion: Sep 2012
Phase 4Completed
NCT04656184Swedish Orphan BiovitrumANAKINRA

A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment

Start: Oct 2023Est. completion: Mar 2027
Phase 3Recruiting
NCT00162032Lantheus Medical ImagingSestamibi

A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease

Start: Aug 2005Est. completion: Dec 2010
Phase 3Completed
NCT02390596Swedish Orphan BiovitrumAnakinra

Anakinra and Kawasaki Disease

Start: Feb 2016Est. completion: Feb 2019
Phase 2Completed
NCT00305201Bristol Myers Squibbpravastatin

Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease

Start: Apr 2006Est. completion: May 20070
Phase 2Withdrawn
NCT00162045Lantheus Medical ImagingTechnetium Tc99m Sestamibi

A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects

Start: Jan 2005Est. completion: Jun 2007
Phase 1/2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials
4 companies competing in this space